📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:48:59时区推断·⟳ 抓取 19:54:20·⚡ 决策 07-30 19:56:50 +2m30s·89.0 天前
辉瑞口服Litfulo在白癜风III期试验中恢复皮肤色素并计划申报
Litfulo两项非节段型白癜风III期研究达到主要终点，对辉瑞新增适应症申报构成利好。
📄 原文Reuters↗ 原文
Pfizer (PFE.N) said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in …
不做 辉瑞（PFE.US）
近72小时已处理消息库在07-30 19:51命中同一具体催化，当前Reuters稿不重复推卡；且辉瑞体量大、未披露可量化收入增量。
不做 Incyte（INCY.US）
同一Litfulo白癜风III期事件已处理过，不重复生成空头或风险；竞品压力方向成立但本轮只作去重回避。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 medium · price-in 风险 high ↗
关键理由
- Litfulo两项非节段型白癜风III期研究达到主要终点，对辉瑞新增适应症申报构成利好。
- 该催化已在近72小时已处理消息库中命中同一具体事件，不能重复推卡或重复延长风险窗口。
- 辉瑞市值约1433亿美元，单一皮肤科适应症扩展对集团短线重定价弹性有限。
主要风险
- Litfulo白癜风适应症仍需监管审批，且商业化增量未在本条快讯中披露。
- Incyte的Opzelura可能面临口服JAK竞品压力，但本次已作为同一催化处理过，不重复生成风险。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中可改变本轮重复判定或支持新增交易的辉瑞Litfulo白癜风商业化量级证据。
检索:Pfizer Litfulo vitiligo phase 3 nonsegmental vitiligo Opzelura competition sales revenue
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,813 字
Pfizer (PFE.N) said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in two late-stage trials, paving the way for regulatory submissions seeking approval in the autoimmune skin disease.
Here are the details:
The U.S. drugmaker was testing Litfulo in patients with nonsegmental vitiligo, the most common type of the disease, which causes patches of skin to lose pigment.
Pfizer said both studies showed significantly more patients treated with the drug achieved at least a 75% improvement in facial repigmentation and at least a 50% improvement in total-body repigmentation after 52 weeks compared with those given placebo.
"Litfulo could become a new oral systemic treatment option for adults living with NSV, significantly improving and potentially maintaining facial and total body repigmentation," Michael Vincent, Pfizer's chief inflammation and immunology officer, said in a statement.
The trials, which enrolled a combined 2,174 patients across 50 mg and 100 mg once-daily doses, were the largest late-stage programs to evaluate an oral treatment for nonsegmental vitiligo, the company said.
The drug works by blocking specific proteins inside immune cells, called JAK3 and TEC family kinases, which helps stop the immune system from attacking the pigment-producing cells in the skin.
Litfulo is already approved in several countries, including the United States, for severe alopecia areata, an autoimmune disorder that causes hair loss.
Pfizer said the drug's safety profile in vitiligo patients was consistent with that seen in studies of alopecia areata, with no new safety signals identified.
Pfizer plans to submit the data to health regulators globally to seek approval for the treatment in adults with nonsegmental vitiligo.
Here are the details:
The U.S. drugmaker was testing Litfulo in patients with nonsegmental vitiligo, the most common type of the disease, which causes patches of skin to lose pigment.
Pfizer said both studies showed significantly more patients treated with the drug achieved at least a 75% improvement in facial repigmentation and at least a 50% improvement in total-body repigmentation after 52 weeks compared with those given placebo.
"Litfulo could become a new oral systemic treatment option for adults living with NSV, significantly improving and potentially maintaining facial and total body repigmentation," Michael Vincent, Pfizer's chief inflammation and immunology officer, said in a statement.
The trials, which enrolled a combined 2,174 patients across 50 mg and 100 mg once-daily doses, were the largest late-stage programs to evaluate an oral treatment for nonsegmental vitiligo, the company said.
The drug works by blocking specific proteins inside immune cells, called JAK3 and TEC family kinases, which helps stop the immune system from attacking the pigment-producing cells in the skin.
Litfulo is already approved in several countries, including the United States, for severe alopecia areata, an autoimmune disorder that causes hair loss.
Pfizer said the drug's safety profile in vitiligo patients was consistent with that seen in studies of alopecia areata, with no new safety signals identified.
Pfizer plans to submit the data to health regulators globally to seek approval for the treatment in adults with nonsegmental vitiligo.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。